Cargando…
Targeting the p53–MDM2 interaction to treat cancer
The tumour suppressor p53 is a transcription factor with powerful antitumour activity that is controlled by its negative regulator MDM2 (mouse double minute 2, also termed HDM2 in humans) through a feedback mechanism. MDM2, which is overproduced in many tumours, binds p53 and inhibits its function b...
Autores principales: | Klein, C, Vassilev, L T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409943/ https://www.ncbi.nlm.nih.gov/pubmed/15452548 http://dx.doi.org/10.1038/sj.bjc.6602164 |
Ejemplares similares
-
Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016) -
Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death
por: Koo, Nayeong, et al.
Publicado: (2022) -
The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019) -
Reduced transcriptional activity in the p53 pathway of senescent
cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009) -
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
por: Traweek, Raymond S., et al.
Publicado: (2022)